A state-of-the-art engineering approach toward improving the neutralizing activity of a cross-reactive nanobody, previously generated against the original SARS virus, showed it can be an attractive ...
Invivyd, Inc. announced new in vitro data demonstrating that its investigational monoclonal antibody PEMGARDA™ (pemivibart) continues to show consistent neutralizing activity against the dominant SARS ...
In a recent study published in Science Immunology, researchers investigated the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron's immune escape mechanisms ...
WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today provided ...
In the cohort that received the BA.5-containing bivalent booster, the neutralizing activity against all the omicron subvariants as compared with that against WA1/2020 was better than in the other two ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve at a rapid pace, generating new variants that arouse concern. Variants that were first detected in California (B.1.429 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results